Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Pulmonary Disease, Chronic Obstructive 1Lung Neoplasms 1Disease 1Diabetes Mellitus, Type 2 1

Interventions

Carboplatin 347pembrolizumab 322Pemetrexed 246Cisplatin 218Paclitaxel 147Nivolumab 138durvalumab 133osimertinib 112Docetaxel 111atezolizumab 109Specimen Handling 91Radiotherapy 87Drug Therapy 85Magnetic Resonance Spectroscopy 77Etoposide 76Radiosurgery 72Gemcitabine 71Ipilimumab 55130-nm albumin-bound paclitaxel 54Bevacizumab 52cemiplimab 47tislelizumab 44Blood Specimen Collection 40Cetuximab 35Taxes 34Platinum 33Injections 33Biopsy 33Standard of Care 31Immunoglobulin G 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sulfonylurea Compounds × Thoracic × 1 year × Clear all
NCT07332156 2026-01-14

Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas

Samsung Medical Center

Completed
21,692 enrolled
Thoracic

Diabetes Mellitus, Type 2, Disease, Lung Neoplasms, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡